Assertio and Garda Delay Tender Offer for Outstanding Shares
Assertio Therapeutics and Garda Capital Partners have mutually agreed to postpone the launch of Garda’s previously announced tender offer for all outstanding Assertio common shares. The companies did not specify a new launch date but said the delay will provide additional time to finalize documentation and regulatory processes.
1. Agreement to Delay Tender Offer Launch
Assertio Therapeutics and Garda Capital Partners have jointly announced a postponement of the planned tender offer for all outstanding Assertio common shares. No revised launch date was provided, as both parties cited the need for extra time to complete offer documentation and satisfy regulatory requirements.
2. Potential Impact on Transaction Timeline
The delay extends the overall acquisition schedule, pushing back the shareholder vote and any subsequent payout. This shift may affect trading activity in Assertio stock and require both companies to adjust their integration and financing strategies as they work toward closing.